Page 23 - College Advantage Newsletter - Fall 2023
P. 23
Fall 2023 23
FDA-APPROVED FOR
5 INDICATIONS
CONSIDER DUPIXENT
FOR YOUR APPROPRIATE PATIENTS
Learn more at Dupixenthcp.com
© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUP.23.03.0192 04/2023 DUPIXENT® is a registered trademark of Sanofi Biotechnology.
